US 12,303,504 B2
Non-aqueous chemotherapeutic suspensions for oral dosage
Vijay Patel, Ahmedabad (IN); Sandip Mehta, Ahmedabad (IN); Manish Kumar Umrethia, Ahmedabad (IN); and Jayanta Mandal, Ahmedabad (IN)
Assigned to ONCOSOL LIMITED, Weedon (GB)
Appl. No. 17/274,432
Filed by ONCOSOL LIMITED, Weedon (GB)
PCT Filed Sep. 13, 2019, PCT No. PCT/IB2019/001044
§ 371(c)(1), (2) Date Mar. 9, 2021,
PCT Pub. No. WO2020/053665, PCT Pub. Date Mar. 19, 2020.
Claims priority of application No. 201821034590 (IN), filed on Sep. 13, 2018.
Prior Publication US 2023/0158018 A1, May 25, 2023
Int. Cl. A61K 31/495 (2006.01); A61K 9/00 (2006.01); A61K 9/10 (2006.01); A61K 31/454 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01)
CPC A61K 31/495 (2013.01) [A61K 9/0053 (2013.01); A61K 9/10 (2013.01); A61K 31/454 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01)] 14 Claims
 
1. A non-aqueous liquid pharmaceutical suspension comprising:
lenalidomide in an amount of about 5 mg/ml;
a polyethoxylated sorbitan ester as a surfactant in an amount of about 1% w/w to about 2% w/w;
a colloidal silica as a suspending agent in an amount of about 1% w/w to about 1.25% w/w;
one or more pharmaceutically acceptable excipients; and
a medium chain fatty acid triglyceride as a vehicle.